David Miller to Risk Assessment
This is a "connection" page, showing publications David Miller has written about Risk Assessment.
Connection Strength
0.277
-
Bellinger C, Pinsky P, Foley K, Case D, Dharod A, Miller D. Lung Cancer Screening Benefits and Harms Stratified by Patient Risk: Information to Improve Patient Decision Aids. Ann Am Thorac Soc. 2019 04; 16(4):512-514.
Score: 0.116
-
Miller DP, Reuland DS. Controversies in cancer screening. N C Med J. 2014 Jul-Aug; 75(4):253-6.
Score: 0.083
-
Miller DP, Watkins SE, Sampson T, Davis KJ. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis. 2011; 6:467-76.
Score: 0.069
-
Zhou W, Liu G, Thurston SW, Xu LL, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan; 11(1):15-21.
Score: 0.009